Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Pharmacol Res. 2020 Aug:158:104939. doi: 10.1016/j.phrs.2020.104939. Epub 2020 May 21.

Abstract

The Coronavirus Disease 2019 (COVID-19) has been declared as a global pandemic, but specific medicines and vaccines are still being developed. In China, interventional therapies with traditional Chinese medicine for COVID-19 have achieved significant clinical efficacies, but the underlying pharmacological mechanisms are still unclear. This article reviewed the etiology of COVID-19 and clinical efficacy. Both network pharmacological study and literature search were used to demonstrate the possible action mechanisms of Chinese medicines in treating COVID-19. We found that Chinese medicines played the role of antivirus, anti-inflammation and immunoregulation, and target organs protection in the management of COVID-19 by multiple components acting on multiple targets at multiple pathways. AEC2 and 3CL protein could be the direct targets for inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Quercetin, kaempferol, luteolin, isorhamnetin, baicalein, naringenin, and wogonin could be the main active ingredients of Chinese medicines for the management of COVID-19 by targeting on AEC2 and 3CL protein and inhibiting inflammatory mediators, regulating immunity, and eliminating free radicals through COX-2, CASP3, IL-6, MAPK1, MAPK14, MAPK8, and REAL in the signaling pathways of IL-17, arachidonic acid, HIF-1, NF-κB, Ras, and TNF. This study may provide meaningful and useful information on further research to investigate the action mechanisms of Chinese medicines against SARS-CoV-2 and also provide a basis for sharing the "China scheme" for COVID-19 treatment.

Keywords: 3CL pro; ACE2; Action mechanism; Baicalein (PubChem CID: 5281605); COVID-19; Isorhamnetin (PubChem CID: 5281654); Kaempferol (PubChem CID: 5280863); Luteolin (PubChem CID: 5280445); Naringenin (PubChem CID: 932); Network pharmacology; Quercetin (PubChem CID: 5280343); Rutin (PubChem CID: 5280805); SARS-CoV-2; Traditional Chinese medicine; Ursolic acid (PubChem CID: 64945); Wogonin (PubChem CID: 5281703); β-Sitosterol (PubChem CID: 222284).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Betacoronavirus / drug effects*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Drugs, Chinese Herbal / pharmacology*
  • Drugs, Chinese Herbal / therapeutic use*
  • Humans
  • Models, Biological
  • Pandemics
  • Phytotherapy*
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2

Substances

  • Drugs, Chinese Herbal